

Felix Gutierrez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6934218/publications.pdf>

Version: 2024-02-01

224
papers

10,534
citations

57758

44
h-index

42399

92
g-index

258
all docs

258
docs citations

258
times ranked

12169
citing authors

#	ARTICLE	IF	CITATIONS
1	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171.	7.4	1,076
2	Dolutegravir plus Abacavir+Lamivudine for the Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 1807-1818.	27.0	697
3	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	13.7	627
4	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	7.4	498
5	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. <i>Lancet, The</i> , 2017, 390, 1499-1510.	13.7	391
6	Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques. <i>PLoS ONE</i> , 2013, 8, e60273.	2.5	329
7	Evaluation of the Immunochromatographic Binax NOW Assay for Detection of <i>Streptococcus pneumoniae</i> Urinary Antigen in a Prospective Study of Community-Acquired Pneumonia in Spain. <i>Clinical Infectious Diseases</i> , 2003, 36, 286-292.	5.8	261
8	Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level Monitoring. <i>Clinical Infectious Diseases</i> , 2005, 41, 1648-1653.	5.8	202
9	The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. <i>Journal of Infection</i> , 2006, 53, 166-174.	3.3	179
10	Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. <i>Aids</i> , 2010, 24, 1697-1707.	2.2	174
11	Usefulness of Procalcitonin Levels in Community-Acquired Pneumonia According to the Patients Outcome Research Team Pneumonia Severity Index. <i>Chest</i> , 2005, 128, 2223-2229.	0.8	171
12	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. <i>PLoS Medicine</i> , 2012, 9, e1001194.	8.4	145
13	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
14	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016, 62, 655-663.	5.8	135
15	Microbiology and Outcome of Iliopsoas Abscess in 124 Patients. <i>Medicine (United States)</i> , 2009, 88, 120-130.	1.0	131
16	Dual treatment with atazanavir+ritonavir plus lamivudine versus triple treatment with atazanavir+ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 775-784.	9.1	122
17	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. <i>Aids</i> , 2012, 26, 2315-2326.	2.2	104
18	Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. <i>Journal of Clinical Immunology</i> , 2021, 41, 1490-1501.	3.8	95

#	ARTICLE	IF	CITATIONS
19	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
20	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	13.7	82
21	Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 29-36.	2.1	81
22	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 698-704.	3.0	76
23	A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 290-297.	2.1	73
24	Influence of Antiretroviral Therapy on Oxidative Stress and Cardiovascular Risk: A Prospective Cross-Sectional Study in HIV-Infected Patients. <i>Clinical Therapeutics</i> , 2007, 29, 1448-1455.	2.5	71
25	Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. <i>EBioMedicine</i> , 2020, 60, 102999.	6.1	71
26	Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. <i>Antiviral Research</i> , 2015, 117, 69-74.	4.1	69
27	Patients Characteristics and Clinical Implications of Suboptimal CD4 T-Cell Gains After 1 Year of Successful Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 100-107.	0.5	66
28	Short Communication: Early Changes in Parathyroid Hormone Concentrations in HIV-Infected Patients Initiating Antiretroviral Therapy with Tenofovir. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 242-246.	1.1	64
29	Delay in the Initiation of HAART, Poorer Virological Response, and Higher Mortality among HIV-Infected Injecting Drug Users in Spain. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 715-723.	1.1	63
30	Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 1579-1587.	5.8	63
31	Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878.	3.2	62
32	Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. <i>Aids</i> , 2010, 24, F1-F9.	2.2	60
33	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	3.3	60
34	High-Density Lipoprotein Cholesterol in HIV-Infected Patients: Evidence for an Association with HIV-1 Viral Load, Antiretroviral Therapy Status, and Regimen Composition. <i>AIDS Patient Care and STDs</i> , 2008, 22, 569-575.	2.5	58
35	Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. <i>Journal of Infection</i> , 2021, 82, 186-230.	3.3	56
36	Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. <i>Aids</i> , 2013, 27, 181-189.	2.2	53

#	ARTICLE	IF	CITATIONS
37	Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 329-337.	2.1	53
38	The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. <i>Atherosclerosis</i> , 2007, 195, 167-171.	0.8	52
39	Decrease in Serial Prevalence of Coinfection with Hepatitis C Virus among HIV-Infected Patients in Spain, 1997-2006. <i>Clinical Infectious Diseases</i> , 2009, 48, 1467-1470.	5.8	52
40	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , 2015, 2, e335-e343.	4.7	52
41	SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab005.	0.9	52
42	Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - Impact of HIV subtypes and prior raltegravir experience. <i>Antiviral Research</i> , 2011, 90, 164-167.	4.1	48
43	Seroprevalence of HIV-1, HBV, HTLV-1 and <i>Treponema pallidum</i> among pregnant women in a rural hospital in Southern Ethiopia. <i>Journal of Clinical Virology</i> , 2011, 51, 83-85.	3.1	46
44	Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. <i>BMC Infectious Diseases</i> , 2012, 12, 169.	2.9	46
45	Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. <i>Aids</i> , 2016, 30, 37-44.	2.2	46
46	Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab059.	0.9	46
47	Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort. <i>PLoS ONE</i> , 2006, 1, e89.	2.5	42
48	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	4.7	42
49	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. <i>AIDS Reviews</i> , 2010, 12, 135-48.	1.0	42
50	The role of HIV and antiretroviral therapy in bone disease. <i>AIDS Reviews</i> , 2011, 13, 109-18.	1.0	42
51	Low Frequency of Renal Function Impairment During One-Year of Therapy with Tenofovir-Containing Regimens in the Real-World: A Case-Control Study. <i>AIDS Patient Care and STDs</i> , 2005, 19, 421-424.	2.5	41
52	Seroprevalence of <i>Toxoplasma gondii</i> infection among immigrant and native pregnant women in Eastern Spain. <i>Parasitology Research</i> , 2011, 109, 1447-1452.	1.6	41
53	Comparison of Combined Nose-Throat Swabs with Nasopharyngeal Aspirates for Detection of Pandemic Influenza A/H1N1 2009 Virus by Real-Time Reverse Transcriptase PCR. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3492-3495.	3.9	40
54	Human Infection with <i>Rickettsia sibirica mongolitimonae</i> , Spain, 2007-2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 267-269.	4.3	40

#	ARTICLE	IF	CITATIONS
55	Oxidative Stress Predicts All-Cause Mortality in HIV-Infected Patients. <i>PLoS ONE</i> , 2016, 11, e0153456.	2.5	40
56	Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. <i>HIV Medicine</i> , 2013, 14, 273-283.	2.2	39
57	Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. <i>Clinical Biochemistry</i> , 2010, 43, 720-724.	1.9	38
58	Endothelial function is impaired in HIV-infected patients with lipodystrophy. <i>Antiviral Therapy</i> , 2010, 15, 101-110.	1.0	37
59	<i>Mycobacterium marinum</i> infection complicated by anti-tumour necrosis factor therapy. <i>Journal of Medical Microbiology</i> , 2010, 59, 617-621.	1.8	37
60	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw097.	0.9	37
61	Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. <i>Journal of Autoimmunity</i> , 2021, 123, 102703.	6.5	37
62	Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. <i>AIDS Reviews</i> , 2014, 16, 199-212.	1.0	36
63	Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. <i>Journal of Infection</i> , 2010, 61, 189-190.	3.3	35
64	Preemptive interleukin-6 blockade in patients with COVID-19. <i>Scientific Reports</i> , 2020, 10, 16826.	3.3	35
65	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. <i>AIDS Reviews</i> , 2012, 14, 208-17.	1.0	35
66	Analysis of Non-AIDS-Defining Events in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2016, 62, 1304-1309.	5.8	34
67	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	5.8	34
68	Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1678-1684.	6.0	34
69	Clinical evaluation of rapid point-of-care testing for detection of novel influenza A (H1N1) virus in a population-based study in Spain. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1358-1361.	6.0	33
70	Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2011, 11, 265.	2.9	33
71	Asociación de obesidad general y abdominal con hipertensión, dislipemia y presencia de prediabetes en el estudio PREDAPS. <i>Revista Española De Cardiología</i> , 2018, 71, 170-177.	1.2	33
72	Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. <i>BMC Infectious Diseases</i> , 2011, 11, 40.	2.9	32

#	ARTICLE	IF	CITATIONS
73	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. <i>Antiviral Research</i> , 2019, 170, 1045-49.	4.1	32
74	Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. <i>HIV Medicine</i> , 2014, 15, 213-223.	2.2	30
75	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. <i>Clinical Infectious Diseases</i> , 2017, 64, 1191-1197.	5.8	30
76	Clinical Utility of Maraviroc. <i>Clinical Drug Investigation</i> , 2011, 31, 527-542.	2.2	29
77	First Human Systemic Infection Caused by Spiroplasma. <i>Journal of Clinical Microbiology</i> , 2015, 53, 719-721.	3.9	29
78	Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. <i>Aids</i> , 2012, 26, 1829-1834.	2.2	27
79	Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. <i>Clinical and Experimental Medicine</i> , 2013, 13, 177-186.	3.6	27
80	Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon- γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, e338-e346.	5.8	27
81	Relationship between ankle-brachial index and carotid intima-media thickness in HIV-infected patients. <i>Aids</i> , 2008, 22, 1369-1371.	2.2	26
82	Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART. <i>Current HIV Research</i> , 2009, 7, 612-619.	0.5	26
83	Performance of Genotypic Algorithms for Predicting HIV-1 Tropism Measured against the Enhanced-Sensitivity Trofile Coreceptor Tropism Assay. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4135-4139.	3.9	26
84	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011, 25, 761-766.	2.2	26
85	Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. <i>Clinical Microbiology and Infection</i> , 2012, 18, E485-E490.	6.0	26
86	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 811-820.	5.8	26
87	Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed antiretroviral treatment and higher mortality. <i>Addiction</i> , 2016, 111, 1235-1245.	3.3	26
88	The CD4/CD8 Ratio is Inversely Associated with Carotid Intima-Media Thickness Progression in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Treatment. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 648-653.	1.1	26
89	Low Prevalence of Peripheral Arterial Disease in HIV-Infected Patients With Multiple Cardiovascular Risk Factors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 126-127.	2.1	25
90	Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. <i>HIV Medicine</i> , 2014, 15, 330-338.	2.2	25

#	ARTICLE	IF	CITATIONS
91	A bibliometric overview of infectious diseases research in European countries (2002–2007). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 713-716.	2.9	24
92	Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio. <i>Medicine (United States)</i> , 2016, 95, e3108.	1.0	24
93	Epidemiology of animal bites and other potential rabies exposures and anti-rabies vaccine utilization in a rural area in Southern Ethiopia. <i>Annals of Agricultural and Environmental Medicine</i> , 2015, 22, 76-79.	1.0	24
94	Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia. <i>Drugs and Aging</i> , 2008, 25, 585-610.	2.7	23
95	The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19643.	3.0	23
96	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1 Infected Patients Treated With Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 21-29.	2.1	23
97	Barriers to health care services for migrants living with HIV in Spain. <i>European Journal of Public Health</i> , 2018, 28, 451-457.	0.3	23
98	Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: A clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension?. <i>Journal of Clinical Virology</i> , 2006, 37, 79-82.	3.1	22
99	Increased Carotid Intima-Media Thickness Associated with Antibody Responses to Varicella-Zoster Virus and Cytomegalovirus in HIV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e64327.	2.5	22
100	Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients. <i>Clinical Science</i> , 2019, 133, 997-1010.	4.3	21
101	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 373-379.	0.5	21
102	Performance of Saliva Specimens for the Molecular Detection of SARS-CoV-2 in the Community Setting: Does Sample Collection Method Matter?. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	21
103	COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. <i>HIV Medicine</i> , 2021, 22, 867-876.	2.2	21
104	Coinfection with Human Herpesvirus 8 Is Associated with Persistent Inflammation and Immune Activation in Virologically Suppressed HIV-Infected Patients. <i>PLoS ONE</i> , 2014, 9, e105442.	2.5	21
105	<i>Trypanosoma cruzi</i> infection in Elche (Spain): comparison of the seroprevalence in immigrants from Paraguay and Bolivia. <i>Pathogens and Global Health</i> , 2012, 106, 102-106.	2.3	20
106	Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir-based antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 653-661.	2.2	20
107	HTLV-1 infection in solid organ transplant donors and recipients in Spain. <i>BMC Infectious Diseases</i> , 2019, 19, 706.	2.9	20
108	Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain. <i>Pathogens and Global Health</i> , 2012, 106, 340-345.	2.3	19

#	ARTICLE	IF	CITATIONS
109	Gender differential on characteristics and outcome of leprosy patients admitted to a long-term care rural hospital in South-Eastern Ethiopia. <i>International Journal for Equity in Health</i> , 2012, 11, 56.	3.5	19
110	Chagas disease in Latin American pregnant immigrants: experience in a non-endemic country. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 919-923.	1.7	19
111	Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 409-413.	3.0	19
112	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004-2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	2.5	19
113	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1693-1700.	3.0	19
114	COVID-19-associated encephalitis successfully treated with combination therapy. <i>Clinical Infection in Practice</i> , 2020, 7-8, 100053.	0.5	19
115	Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164.	1.1	18
116	Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection. <i>Renal Failure</i> , 2010, 32, 518-522.	2.1	17
117	Treatment for hepatitis C virus with pegylated interferon- α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1861-1868.	3.0	17
118	Short-Term and Long-Term Clinical and Immunological Consequences of Stopping Antiretroviral Therapy in HIV-Infected Patients with Preserved Immune Function. <i>Antiviral Therapy</i> , 2013, 18, 125-130.	1.0	17
119	Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2257-2264.	3.0	17
120	Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 439-451.	0.5	16
121	Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-based Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz491.	0.9	16
122	Asma y EPOC en pacientes hospitalizados por COVID-19. <i>Archivos De Bronconeumologia</i> , 2020, 56, 604-606.	0.8	16
123	HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. <i>AIDS Reviews</i> , 2009, 11, 39-51.	1.0	16
124	Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5185-5196.	3.2	15
125	A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 589-598.	3.0	15
126	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. <i>Atherosclerosis</i> , 2018, 273, 28-36.	0.8	15

#	ARTICLE	IF	CITATIONS
127	X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. <i>Aids</i> , 2014, 28, 1603-1609.	2.2	14
128	HIV co-infection in HTLV-1 carriers in Spain. <i>Virus Research</i> , 2019, 266, 48-51.	2.2	14
129	Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471.	2.2	13
130	Mapping of Chagas disease research: analysis of publications in the period between 1940 and 2009. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2011, 44, 708-716.	0.9	13
131	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3087-3095.	3.0	13
132	Severe skull base osteomyelitis caused by <i>Pseudomonas aeruginosa</i> with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 48.	0.8	13
133	Cervicitis: etiología, diagnóstico y tratamiento. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 661-667.	0.5	13
134	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. <i>Journal of Infectious Diseases</i> , 2022, 225, 1040-1049.	4.0	13
135	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2380-2393.	3.0	13
136	Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 749657.	2.6	13
137	A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 51-58.	2.1	12
138	Rubella immune status among immigrant and nonimmigrant women in Spain. <i>Journal of Medical Virology</i> , 2012, 84, 548-550.	5.0	12
139	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 517-523.	0.5	12
140	Riesgo de cáncer en personas con VIH en España, 2004-2015. Estudio de la cohorte CoRIS. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 502-508.	0.5	12
141	Statins in HIV-Infected Patients: Potential Beneficial Effects and Clinical Use. <i>AIDS Reviews</i> , 2017, 19, 59-71.	1.0	12
142	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 516.e1-516.e18.	0.5	11
143	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 377-383.	0.5	11
144	Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015. <i>PLoS ONE</i> , 2019, 14, e0215507.	2.5	11

#	ARTICLE	IF	CITATIONS
145	Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunosuppression. <i>PLoS ONE</i> , 2019, 14, e0214421.	2.5	11
146	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.5	10
147	Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, e36-e44.	2.1	10
148	Developments in early diagnosis and therapy of HIV infection in newborns. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 13-25.	1.8	10
149	Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 48-57.	1.1	10
150	Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19. <i>Journal of Infection</i> , 2021, 82, 414-451.	3.3	10
151	Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study. <i>HIV Medicine</i> , 2012, 13, 488-498.	2.2	9
152	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002.	3.0	9
153	Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions. <i>Frontiers in Microbiology</i> , 2019, 10, 370.	3.5	9
154	VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Naïve HIV-Infected Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 311.	2.4	9
155	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 195-202.	0.5	9
156	Geography of medical publications. An overview of HIV/AIDS research in 2003. <i>Aids</i> , 2005, 19, 219-220.	2.2	8
157	First case of post-endoscopic retrograde cholangiopancreatography bacteraemia caused by <i>Acinetobacter ursingii</i> in a patient with choledocholithiasis and cholangitis. <i>Journal of Medical Microbiology</i> , 2008, 57, 1170-1171.	1.8	8
158	Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020.	3.2	8
159	Predictors of Pneumococcal Co-infection for Patients with Pandemic (H1N1) 2009 Influenza. <i>Emerging Infectious Diseases</i> , 2011, 17, 1475-8.	4.3	8
160	Recurrence of active tuberculosis following resumption of anti-TNF therapy in a patient with Crohn's disease [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 249-250.	1.2	8
161	Long-term effects of an intensive intervention in HIV-infected patients with moderate-to-high atherosclerotic cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3051-3056.	3.0	8
162	Impact of Prior Virological Failure and Nucleos(t)ide Genotypic Resistance Mutations on the Efficacy of Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. <i>Antiviral Therapy</i> , 2015, 20, 487-492.	1.0	8

#	ARTICLE	IF	CITATIONS
163	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 409.e5-409.e8.	6.0	8
164	Decreasing rates of acute myocardial infarction in people living with HIV: a nationwide cohort study in Spain, 2004–2015. <i>HIV Medicine</i> , 2018, 19, 491-496.	2.2	8
165	Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz036.	0.9	8
166	Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 668-674.	3.0	8
167	Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial. <i>PLoS ONE</i> , 2017, 12, e0175634.	2.5	8
168	Consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014, 34 Suppl 2, 1-81.	0.4	8
169	Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade. <i>EBioMedicine</i> , 2022, 82, 104153.	6.1	8
170	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2011, 17, 577-583.	1.0	7
171	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68.	2.0	7
172	Effectiveness and safety of an abacavir/lamivudine+rilpivirine regimen for the treatment of HIV-1 infection in naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3510-3514.	3.0	7
173	Executive summary of the consensus document on osteoporosis in HIV-infected individuals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 312-314.	0.5	7
174	CD4 recovery is associated with genetic variation in IFN β and IL19 genes. <i>Antiviral Research</i> , 2019, 170, 104577.	4.1	7
175	Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. <i>PLoS ONE</i> , 2019, 14, e0221598.	2.5	7
176	Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611986802.	1.8	7
177	Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. <i>Journal of Clinical Virology</i> , 2011, 51, 192-194.	3.1	6
178	Prevalence of HIV, HBV, HCV, HTLV and <i>Treponema pallidum</i> among patients attending a rural hospital in Southern Ethiopia. <i>Journal of Clinical Virology</i> , 2012, 53, 268-269.	3.1	6
179	Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen. <i>HIV Medicine</i> , 2014, 15, 547-556.	2.2	6
180	Boosted Lopinavir Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	5.8	6

#	ARTICLE	IF	CITATIONS
181	Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2444-2451.	3.0	6
182	Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106142.	2.5	6
183	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3517-3524.	3.0	6
184	Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. <i>PLoS ONE</i> , 2017, 12, e0184329.	2.5	6
185	Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. <i>Emerging Infectious Diseases</i> , 2011, 17, 1116-1119.	4.3	6
186	Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. <i>Trials</i> , 2021, 22, 851.	1.6	6
187	Anal tuberculosis complicating anti-TNF therapy. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014206976-bcr2014206976.	0.5	5
188	High-grade anal intraepithelial neoplasia is associated with HIV-1 RNA rectal shedding in virologically suppressed MSM. <i>Aids</i> , 2018, 32, 1017-1024.	2.2	5
189	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrologia</i> , 2019, 39, 497-505.	0.4	5
190	Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3004-3014.	3.0	5
191	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3334-3343.	3.0	5
192	Incidence of delayed asymptomatic COVID-19 recurrences in a 6-month longitudinal study. <i>Journal of Infection</i> , 2021, 82, 276-316.	3.3	5
193	Executive summary of the Consensus Document of GeSIDA and Spanish Secretariat for the National Plan on AIDS on combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 604-613.	0.5	4
194	CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19656.	3.0	4
195	Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 41-47.	0.5	4
196	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2017, 22, 21-29.	1.0	4
197	Evaluation of the Virclia [®] automated chemiluminescent immunoassay system for diagnosing pneumonia caused by <i>Mycoplasma pneumoniae</i> . <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22431.	2.1	4
198	Performance of the cobas u 701 Analyzer in Urinary Tract Infection Screening. <i>Annals of Laboratory Medicine</i> , 2019, 39, 464-469.	2.5	4

#	ARTICLE	IF	CITATIONS
199	Risk of cancer in HIV-infected patients in Spain, 2004–2015. The CoRIS cohort study. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 502-508.	0.3	4
200	Infection With <i>Chlamydia trachomatis</i> Increases the Risk of High-grade Anal Intraepithelial Neoplasia in People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 70, 2161-2167.	5.8	4
201	Psychological distress in women and men living with HIV in Spain: a cross-sectional telephone survey. <i>Evidence-Based Mental Health</i> , 2020, 23, 91-99.	4.5	4
202	Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. <i>Emerging Infectious Diseases</i> , 2011, 17, 1116-1119.	4.3	4
203	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010–2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 580-587.	0.5	4
204	Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. <i>BMC Women's Health</i> , 2018, 18, 24.	2.0	3
205	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 373-379.	0.3	3
206	Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017). <i>Scientific Reports</i> , 2020, 10, 16891.	3.3	3
207	Diabetes Does Not Increase the Risk of Hospitalization Due to COVID-19 in Patients Aged 50 Years or Older in Primary Care—APHOSDIAB—COVID-19 Multicenter Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2092.	2.4	3
208	Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19520.	3.0	2
209	Infección por el VIH/sida: ¿El principio del fin de la primera gran pandemia contemporánea?. <i>Revista Clínica Española</i> , 2017, 217, 468-472.	0.6	2
210	Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort. <i>Antiviral Therapy</i> , 2021, 25, 335-340.	1.0	2
211	Considerations on ankle-brachial index interpretation in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 395-395.	2.2	1
212	Idiopathic ileocolitis with perforation associated with HIV infection: thalidomide treatment. <i>International Journal of STD and AIDS</i> , 2012, 23, 830-832.	1.1	1
213	Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. <i>HIV Medicine</i> , 2017, 18, 482-489.	2.2	1
214	Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 457.	0.5	1
215	Contribution of Human Herpesvirus 8 and Herpes Simplex Type 2 to Progression of Carotid Intima-Media Thickness in People Living With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz041.	0.9	1
216	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrología</i> , 2019, 39, 497-505.	0.4	1

#	ARTICLE	IF	CITATIONS
217	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. <i>AIDS Research and Therapy</i> , 2020, 17, 45.	1.7	1
218	Remission of minimal change disease in Type 2 diabetes after streptococcus bacteremia. <i>Clinical Nephrology</i> , 2009, 71, 179-182.	0.7	1
219	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. <i>Nefrología</i> , 2014, 34, 768-88.	0.4	1
220	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2012, 17, 597.	1.0	0
221	Vitamin D deficiency: One more piece of the puzzle of cardiovascular risk in human immunodeficiency virus-infected patients?. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 118-120.	0.2	0
222	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 377-383.	0.3	0
223	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020, 21, 128-134.	2.2	0
224	Late reinfection with a different severe acute respiratory syndrome coronavirus-2 clade in a patient with refractory arterial hypertension: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 454.	0.8	0